Medindia

X

Cyntellect Launches CellXpress(TM) System to Boost Productivity of Biopharmaceutical Process Development

Monday, September 22, 2008 General News J E 4
Advertisement
SAN DIEGO, Sept. 22 Cyntellect, a privately-held lifesciences company leading the development and commercialization of live-cellanalysis and manipulation systems, announced today the launch of CellXpress,powered by the Company's proprietary laser-based system LEAP(TM). Theautomated system brings new improvements in speed, cost and optimal cloneselection for cell line development. Biopharmaceutical teams developingmanufacturing cell lines for potential medicines can now reduce the timerequired to get to clinical testing, decrease production costs of proteintherapeutics and substantially increase the number of development projectswhich can be processed in parallel.

CellXpress can be purchased by customers directly from Cyntellect in theU.S. and Europe and from Cyntellect's distribution partner, SummitPharmaceuticals, in Japan.

The CellXpress system exploits high-speed imaging of living cells combinedwith simultaneous laser elimination of undesired cells, leaving behind cellsthat are efficiently secreting biopharmaceutical proteins. The process isinitiated by imaging thousands of cells per well to quantify the level ofprotein being secreted by each cell. This unique measurement is enabled byCyntellect's proprietary in situ assay for capturing and labeling secretedprotein around living individual cells. The best secreting cell is located inseconds within a pool of thousands of candidate cells, and once located; allother undesired cells are selectively eliminated with the laser leaving behindonly the best cell. This purification results in a verified clone that isvery likely to generate a highly secreting cell lines. The imaging andpurification processes can be repeated hundreds of times an hour to enablescanning through millions of cells per day, often yielding hundreds ofhighly-secreting clones. In contrast, current manual and semi-automatedapproaches are able to screen through thousands of cells per day and oftenyield tens of clones following many weeks of growth and assessment.

"The increasing pressures on bioprocess development teams to improvemanufacturing productivity and shorten timelines have not been adequatelyaddressed," said Fred Koller, Ph.D., Cyntellect's President and ChiefExecutive Officer. "Our goal with CellXpress is to provide a reliable,scalable and efficient product that customers can purchase and use in-house toempower significant productivity gains, while also helping get new potentialdrugs to market sooner."

Previously, CellXpress was available only as a fee for service from SAFCBiosciences. Now, customers can purchase the technology as a product directlyfrom Cyntellect and its distributors allowing bioprocessing teams to harvestthe productivity benefits of CellXpress as part of their in-house programs.

About Cyntellect

Cyntellect, Inc. is a life sciences company committed to revolutionizingthe use of living cells in life science research and cellular therapy. TheCompany combines expertise in high-speed cell imaging and laser-basedmanipulation to develop products that enable novel cell imaging, purification,and transfection capabilities to enhance the productivity of laboratoryresearch, recombinant protein production, high-content cellular assays,functional genomics and proteomics, and cell purification, includingprocessing of cells for therapeutic transplantation. For additionalinformation please visit the Company's web site at www.cyntellect.com.The CellXpress system can provide significant benefits to customers by: -- Yielding verified highly-secreting single-cell clones in less than 24 hours (vs. weeks) -- Isolating ten-fold more highly secreting clones than traditional methods -- Selecting optimal clones based on real-time assessment of secretion, growth and stability -- Reducing time to confirmed highly-secreting clones by more than 50% --
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Derma Sciences' MEDIHONEY(TM) Abstract Available O...
S
Webcast Alert: ATL/TV1102 Phase II Results Present...